ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

ESR1

estrogen receptor 1 · also ER, NR3A1, Era, ER-alpha · Estrogen receptors

15 programs in company-led studies act on ESR1, from 12 companies: 9 in phase 3, 5 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (12 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
FulvestrantruleAstraZenecaantagonistphase 4305 running–ChEMBL
TamoxifenruleAstraZeneca–phase 4214 running–ChEMBL
Ethinyl EstradiolruleJohnson & Johnsonagonistphase 4701 running–ChEMBL
EstradiolruleNovo Nordiskagonistphase 4691 running–ChEMBL
ClomipheneruleHamad Medical–phase 431 running–ChEMBL
giredestrantHoffmann-La Rochedegraderphase 31712 running–a judged reading
HRS-8080Jiangsu HengRui Medicine–phase 31310 running–the company's pipeline
camizestrantruleAstraZenecadegraderphase 3189 running–NCIt
vepdegestrantrulePfizerdegraderphase 3206 running–NCIt
ImlunestrantruleEli Lillydegraderphase 3126 running–NCIt
elacestrantruleMenarini Groupdegraderphase 3125 running–NCIt
SIM0270ruleSimcere Pharmaceutical Groupdegraderphase 354 running–the studies' text
palazestrantruleOlema Pharmaceuticalsantagonistphase 343 running–NCIt
taragarestrantruleInventisBiodegraderphase 351 running–NCIt
Estrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0117Johnson & Johnson–phase 111 running–a judged reading

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.